BioVie Inc. (NASDAQ:BIVI) Short Interest Update

BioVie Inc. (NASDAQ:BIVI) was the target of a significant decline in short interest during the month of April. As of April 15th, there was short interest totaling 129,231 shares, a decline of 16.2% from the March 31st total of 154,206 shares. Based on an average trading volume of 55,969 shares, the days-to-cover ratio is presently 2.3 days. Currently, 1.7% of the company’s stock are sold short.

BioVie Trading Up 1.5%

BIVI opened at $1.68 on Friday. The business’s 50 day moving average is $1.41 and its 200-day moving average is $1.42. The stock has a market cap of $12.63 million, a PE ratio of -0.52 and a beta of 0.56. BioVie has a twelve month low of $1.06 and a twelve month high of $13.20.

BioVie (NASDAQ:BIVI) last posted its earnings results on Friday, February 6th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.04.

Institutional Investors Weigh In On BioVie

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Prelude Capital Management LLC acquired a new stake in BioVie in the third quarter worth about $275,000. Prosperity Wealth Management Inc. bought a new stake in BioVie during the third quarter worth approximately $273,000. DRW Securities LLC bought a new position in BioVie during the 4th quarter valued at $149,000. Citadel Advisors LLC acquired a new stake in BioVie in the 3rd quarter valued at about $199,000. Finally, Jane Street Group LLC bought a new stake in shares of BioVie during the 2nd quarter worth $57,000. 4.59% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioVie in a research report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, BioVie has an average rating of “Sell”.

BioVie Company Profile

BioVie Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease.